EA201691413A1 - Селективные антагонисты nr2b - Google Patents
Селективные антагонисты nr2bInfo
- Publication number
- EA201691413A1 EA201691413A1 EA201691413A EA201691413A EA201691413A1 EA 201691413 A1 EA201691413 A1 EA 201691413A1 EA 201691413 A EA201691413 A EA 201691413A EA 201691413 A EA201691413 A EA 201691413A EA 201691413 A1 EA201691413 A1 EA 201691413A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- nr2b
- selective antagonists
- compounds
- ligands
- salts
- Prior art date
Links
- 102000034527 Retinoid X Receptors Human genes 0.000 title abstract 2
- 108010038912 Retinoid X Receptors Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461925363P | 2014-01-09 | 2014-01-09 | |
| PCT/US2015/010262 WO2015105772A1 (en) | 2014-01-09 | 2015-01-06 | Selective nr2b antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201691413A1 true EA201691413A1 (ru) | 2016-10-31 |
Family
ID=52463126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201691413A EA201691413A1 (ru) | 2014-01-09 | 2015-01-06 | Селективные антагонисты nr2b |
Country Status (28)
| Country | Link |
|---|---|
| US (10) | US9221796B2 (https=) |
| EP (1) | EP3092224B1 (https=) |
| JP (1) | JP6543259B2 (https=) |
| KR (1) | KR102311518B1 (https=) |
| CN (1) | CN106061961B (https=) |
| AR (1) | AR099071A1 (https=) |
| AU (1) | AU2015205001A1 (https=) |
| CA (1) | CA2936293A1 (https=) |
| CL (1) | CL2016001763A1 (https=) |
| DK (1) | DK3092224T3 (https=) |
| EA (1) | EA201691413A1 (https=) |
| ES (1) | ES2693250T3 (https=) |
| HR (1) | HRP20181585T1 (https=) |
| HU (1) | HUE041986T2 (https=) |
| IL (1) | IL246599A0 (https=) |
| LT (1) | LT3092224T (https=) |
| MX (1) | MX2016008898A (https=) |
| PE (1) | PE20160933A1 (https=) |
| PL (1) | PL3092224T3 (https=) |
| PT (1) | PT3092224T (https=) |
| RS (1) | RS57830B1 (https=) |
| SG (1) | SG11201605618WA (https=) |
| SI (1) | SI3092224T1 (https=) |
| SM (1) | SMT201800619T1 (https=) |
| TR (1) | TR201815579T4 (https=) |
| TW (1) | TWI640515B (https=) |
| UY (1) | UY35947A (https=) |
| WO (1) | WO2015105772A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9221796B2 (en) * | 2014-01-09 | 2015-12-29 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
| KR102613179B1 (ko) * | 2015-06-01 | 2023-12-14 | 뤼겐 홀딩스 (케이맨) 리미티드 | Nr2b nmda 수용체 길항제로서의 3,3-디플루오로피페리딘 카바메이트 헤테로사이클릭 화합물 |
| BR112018007181A2 (pt) * | 2015-10-14 | 2018-10-16 | Bristol-Myers Squibb Company | antagonistas de nr2b seletivos |
| KR20180063306A (ko) * | 2015-10-14 | 2018-06-11 | 브리스톨-마이어스 스큅 컴퍼니 | 선택적 nr2b 길항제 |
| US11000526B2 (en) | 2016-11-22 | 2021-05-11 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
| CN108203404A (zh) * | 2018-03-02 | 2018-06-26 | 上海博邦医药科技有限公司 | (r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法 |
| US10781172B2 (en) | 2018-06-21 | 2020-09-22 | Northwestern University | Catalysts and methods for enantioselective conjugate additions of amines to unsaturated electrophiles |
| WO2024197289A1 (en) * | 2023-03-22 | 2024-09-26 | Gilgamesh Pharmaceuticals, Inc. | Negative allosteric modulators of glun2b receptors and methods of making and using the same |
| WO2025113519A1 (zh) * | 2023-11-28 | 2025-06-05 | 成都地奥制药集团有限公司 | 内酰胺环类化合物及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2744448B1 (fr) | 1996-02-02 | 1998-04-24 | Pf Medicament | Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments |
| WO2000063173A1 (en) | 1999-04-14 | 2000-10-26 | F. Hoffmann-La Roche Ag | Process for the preparation of substituted piperidines |
| US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| MXPA02009659A (es) * | 2000-04-26 | 2003-03-10 | Warner Lambert Co | Derivado de ciclohexilamina como subtipo de los antagonistas del receptor selectivo nmda. |
| JPWO2003035641A1 (ja) | 2001-10-22 | 2005-02-10 | 塩野義製薬株式会社 | 新規カルバモイルピロリドン誘導体 |
| SI1648882T1 (sl) | 2003-06-04 | 2009-02-28 | Merck & Co Inc | 3-fluoro-piperidini kot nmda/nr2b antagonisti |
| WO2005035523A1 (en) | 2003-10-08 | 2005-04-21 | Pfizer Japan Inc. | Fused lactam compounds |
| EP2520567A3 (en) | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| EA201070077A1 (ru) | 2007-06-29 | 2010-08-30 | Эмори Юниверсити | Антагонисты nmda-рецепторов с нейропротективным действием |
| US9221796B2 (en) * | 2014-01-09 | 2015-12-29 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
-
2015
- 2015-01-05 US US14/589,205 patent/US9221796B2/en active Active
- 2015-01-06 RS RS20181296A patent/RS57830B1/sr unknown
- 2015-01-06 CN CN201580012735.9A patent/CN106061961B/zh not_active Expired - Fee Related
- 2015-01-06 SM SM20180619T patent/SMT201800619T1/it unknown
- 2015-01-06 WO PCT/US2015/010262 patent/WO2015105772A1/en not_active Ceased
- 2015-01-06 EA EA201691413A patent/EA201691413A1/ru unknown
- 2015-01-06 AU AU2015205001A patent/AU2015205001A1/en not_active Abandoned
- 2015-01-06 EP EP15703328.3A patent/EP3092224B1/en active Active
- 2015-01-06 PE PE2016001107A patent/PE20160933A1/es not_active Application Discontinuation
- 2015-01-06 ES ES15703328.3T patent/ES2693250T3/es active Active
- 2015-01-06 MX MX2016008898A patent/MX2016008898A/es unknown
- 2015-01-06 LT LTEP15703328.3T patent/LT3092224T/lt unknown
- 2015-01-06 HU HUE15703328A patent/HUE041986T2/hu unknown
- 2015-01-06 KR KR1020167021356A patent/KR102311518B1/ko not_active Expired - Fee Related
- 2015-01-06 TR TR2018/15579T patent/TR201815579T4/tr unknown
- 2015-01-06 CA CA2936293A patent/CA2936293A1/en not_active Abandoned
- 2015-01-06 HR HRP20181585TT patent/HRP20181585T1/hr unknown
- 2015-01-06 DK DK15703328.3T patent/DK3092224T3/en active
- 2015-01-06 JP JP2016545819A patent/JP6543259B2/ja not_active Expired - Fee Related
- 2015-01-06 SG SG11201605618WA patent/SG11201605618WA/en unknown
- 2015-01-06 PL PL15703328T patent/PL3092224T3/pl unknown
- 2015-01-06 PT PT15703328T patent/PT3092224T/pt unknown
- 2015-01-06 SI SI201530408T patent/SI3092224T1/sl unknown
- 2015-01-08 TW TW104100592A patent/TWI640515B/zh not_active IP Right Cessation
- 2015-01-09 AR ARP150100065A patent/AR099071A1/es unknown
- 2015-01-09 UY UY0001035947A patent/UY35947A/es unknown
- 2015-10-13 US US14/882,041 patent/US20160081995A1/en not_active Abandoned
-
2016
- 2016-07-04 IL IL246599A patent/IL246599A0/en unknown
- 2016-07-08 CL CL2016001763A patent/CL2016001763A1/es unknown
-
2017
- 2017-05-25 US US15/604,904 patent/US20170258777A1/en not_active Abandoned
- 2017-09-15 US US15/706,172 patent/US20180000807A1/en not_active Abandoned
- 2017-12-19 US US15/846,672 patent/US20180110766A1/en not_active Abandoned
-
2018
- 2018-05-04 US US15/971,067 patent/US20180250283A1/en not_active Abandoned
- 2018-12-19 US US16/225,850 patent/US20190117638A1/en not_active Abandoned
-
2019
- 2019-06-27 US US16/454,831 patent/US20190314358A1/en not_active Abandoned
-
2020
- 2020-01-30 US US16/777,114 patent/US20200163949A1/en not_active Abandoned
- 2020-09-04 US US17/012,781 patent/US20210121453A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201691413A1 (ru) | Селективные антагонисты nr2b | |
| EA201691070A1 (ru) | Новые трициклические соединения в качестве противораковых средств | |
| EA201690846A1 (ru) | Замещенные производные пиридина, пригодные в качестве ингибиторов gsk-3 | |
| EA201391332A1 (ru) | Лиганды опиоидных рецепторов и способы их применения и получения | |
| EA201692177A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| EA201792535A1 (ru) | Гетероциклические амиды в качестве ингибиторов киназ | |
| EA201891251A1 (ru) | Бициклические ингибиторы pad4 | |
| EA201891910A1 (ru) | Гетероарильные ингибиторы pad4 | |
| EA201790764A1 (ru) | Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1 | |
| EA201691272A1 (ru) | Тетрагидропиридопиразины в качестве модуляторов gpr6 | |
| EA201691442A1 (ru) | N-азаспироциклоалканзамещенные n-гетероарильные соединения и композиции для ингибирования активности shp2 | |
| EA201690844A1 (ru) | Ингибиторы gsk-3 | |
| MX388170B (es) | Polimorfos de selinexor | |
| EA201290940A1 (ru) | Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами | |
| EA201791058A1 (ru) | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) | |
| EA201890245A1 (ru) | Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b | |
| EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
| EA201691541A1 (ru) | Новые анти-baff антитела | |
| EA201891347A1 (ru) | Аза-бензимидазольные ингибиторы pad4 | |
| EA201790519A1 (ru) | Терапевтические соединения в качестве ингибиторов рецептора орексина-1 | |
| EA201791259A1 (ru) | Производные пиперидина в качестве ингибиторов hdac1/2 | |
| EA201791096A1 (ru) | 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139 | |
| EA201691141A1 (ru) | Соединения против ccr6 | |
| EA201700042A1 (ru) | Соединения имидазопиридазина | |
| EA201891710A1 (ru) | Терапевтические соединения |